Dow Jones Industrial Average ETF vs Twist Bioscience Corp — how do they compare? Dow Jones Industrial Average ETF trades at $511.94 (market cap $45.20B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Dow Jones Industrial Average ETF is far larger — about 4.5× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is more actively traded (4,229,037 versus 4,095,368). Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and Twist Bioscience Corp for 27 Days on average.
| DIA | TWST | |
|---|---|---|
Market Cap | $45.20B | $10.08B |
Volume | 4,095,368 | 4,229,037 |
52-Week High | $542.79 | $205.00 |
52-Week Low | $451.37 | $25.45 |
Typical Hold Time | 103 Days | 27 Days |
Sector | — | Health |
Enterprise Value | — | $10.01B |
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $511.02, down 0.68% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF provides exposure to the 30 blue-chip Dow Jones Industrial Average components, offering diversified large-cap value. Recent dividend distributions in 2026 provide income, while broader market sentiment reflects caution amid economic uncertainty and Federal Reserve policy focus.
The outlook for DIA hinges on the performance of the Dow 30 constituents, with potential upside from strong corporate earnings but risks from high bond yields and market volatility. As a passive ETF, its value tracks the index, making macroeconomic trends and interest rate expectations key drivers. Current technical weakness near support at $509 suggests near-term pressure, though long-term investors may find stability in its blue-chip holdings.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →